Chromocell Therapeutics Corp CHRO
We take great care to ensure that the data presented and summarized in this overview for Chromocell Therapeutics Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in CHRO
Top Purchases
Top Sells
About CHRO
Insider Transactions at CHRO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 23
2025
|
Andrew J. Einhorn Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+50.0%
|
-
|
|
Dec 10
2025
|
Matthew Pauls Director |
SELL
Bona fide gift
|
Direct |
9,542
-89.88%
|
-
|
|
Nov 25
2025
|
Ezra M Friedberg Director |
SELL
Open market or private sale
|
Indirect |
10,000
-6.78%
|
$280,000
$28.16 P/Share
|
|
Oct 02
2025
|
Matthew Pauls Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,123
+16.67%
|
-
|
|
Jul 02
2025
|
Matthew Pauls Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,493
+50.0%
|
-
|
|
Jul 01
2025
|
Ezra M Friedberg Director |
BUY
Conversion of derivative security
|
Indirect |
80,000
+50.0%
|
$800,000
$10.0 P/Share
|
|
Jul 01
2025
|
Todd C Davis Director |
BUY
Conversion of derivative security
|
Indirect |
1,500,000
+50.0%
|
$15,000,000
$10.0 P/Share
|
|
Jul 01
2025
|
Knuettel Francis Ii CFO, Treas & Secty |
BUY
Conversion of derivative security
|
Indirect |
10,000
+50.0%
|
$100,000
$10.0 P/Share
|
|
Jul 01
2025
|
Ligand Pharmaceuticals Inc |
BUY
Conversion of derivative security
|
Direct |
1,500,000
+50.0%
|
$15,000,000
$10.0 P/Share
|
|
Sep 13
2024
|
Knuettel Francis Ii CFO, Treas & Secty |
BUY
Open market or private purchase
|
Indirect |
3,500
+0.64%
|
$0
$0.97 P/Share
|
|
Sep 12
2024
|
Knuettel Francis Ii CFO, Treas & Secty |
BUY
Open market or private purchase
|
Indirect |
1,700
+0.31%
|
$0
$0.97 P/Share
|
|
Sep 12
2024
|
Richard Malamut Director |
BUY
Open market or private purchase
|
Indirect |
10,400
+10.2%
|
$0
$0.94 P/Share
|
|
Sep 11
2024
|
Knuettel Francis Ii CFO, Treas & Secty |
BUY
Open market or private purchase
|
Indirect |
5,500
+1.0%
|
$0
$0.94 P/Share
|
|
Sep 10
2024
|
Knuettel Francis Ii CFO, Treas & Secty |
BUY
Open market or private purchase
|
Indirect |
6,500
+1.2%
|
$0
$0.89 P/Share
|
|
Jun 28
2024
|
Knuettel Francis Ii CFO, Treas & Secty |
SELL
Bona fide gift
|
Direct |
20,000
-1.88%
|
-
|
|
Feb 21
2024
|
Todd C Davis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
29,167
+50.0%
|
$116,668
$4.8 P/Share
|
|
Feb 21
2024
|
Ezra M Friedberg Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
20,641
+1.96%
|
$82,564
$4.8 P/Share
|
Last 12 Months Summary
Buy / Acquisition
3.11M
Shares
From
6
Insiders
| Conversion of derivative security | 3.09M shares |
|---|---|
| Exercise of conversion of derivative security | 10.6K shares |
| Grant, award, or other acquisition | 12K shares |
Sell / Disposition
19.5K
Shares
From
2
Insiders
| Open market or private sale | 10K shares |
|---|---|
| Bona fide gift | 9.54K shares |